USPTO Patent Application: Nucleoside Derivative for Inflammation Treatment

ChangeBridge: Patent Apps - Pharma (A61K)

Published December 2nd, 2025

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083743A1) detailing a nucleoside derivative for preventing and treating inflammation. The application, filed by WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY, claims the derivative offers better efficacy and fewer side effects than existing treatments like indometacin.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has published patent application US20260083743A1, filed by WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY. The application describes a novel nucleoside derivative intended for the prevention and treatment of inflammatory diseases, including pancreatitis, hepatitis, and arthritis. It asserts that this derivative demonstrates superior efficacy and a significantly better side effect profile compared to established anti-inflammatory drugs such as indometacin, aspirin, ibuprofen, and glucocorticoids.

This publication represents a new patent application and does not impose immediate regulatory obligations on pharmaceutical companies or drug manufacturers. However, it signifies potential future intellectual property rights and market exclusivity for the assignee. Companies involved in the development of anti-inflammatory drugs should be aware of this filing as it may impact their research and development strategies and competitive landscape in the pharmaceutical sector.

Source document (simplified)

← USPTO Patent Applications

NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF

Application US20260083743A1 Kind: A1 Mar 26, 2026

Assignee

WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY

Inventors

Wen Huang

Abstract

The present invention provides a nucleoside derivative for preventing and treating inflammation and an application thereof in the preparation of a drug for preventing and treating inflammatory diseases. The nucleoside derivative for preventing and treating inflammation provided by the present invention can significantly ameliorate conditions of pancreatitis, hepatitis, arthritis and the like, ameliorate organ injury and inflammatory indexes, and have better effects than positive control drug, indometacin. Compared with the conventional anti-inflammatory drugs, aspirin, ibuprofen, indomethacin, phenylbutazone, diclofenac, piroxicam and glucocorticoids, the nucleoside derivative for preventing and treating inflammation provided by the present invention has the advantage of significantly fewer side effects.